169 related articles for article (PubMed ID: 32885780)
21. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
22. Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain.
Stoffel S; Benito L; Milà N; Travier N; Binefa G; Vidal C; Espinosa J; Moreno V; Garcia M
Prev Med; 2019 Feb; 119():58-62. PubMed ID: 30594532
[TBL] [Abstract][Full Text] [Related]
23. Invitation letter with a standardized form is a reliable tool to exclude increased risk patients from organized fecal immunological testing-based colorectal cancer screening program.
Sportes A; Catajar N; Charles S; Bejou B; Mary F; Sabaté JM; Le Mab G; Benamouzig R
Dig Liver Dis; 2018 Dec; 50(12):1339-1342. PubMed ID: 29571900
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial.
Coronado GD; Petrik AF; Vollmer WM; Taplin SH; Keast EM; Fields S; Green BB
JAMA Intern Med; 2018 Sep; 178(9):1174-1181. PubMed ID: 30083752
[TBL] [Abstract][Full Text] [Related]
25. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
[TBL] [Abstract][Full Text] [Related]
27. Offering people a choice for colorectal cancer screening.
Senore C; Ederle A; Benazzato L; Arrigoni A; Silvani M; Fantin A; Fracchia M; Armaroli P; Segnan N
Gut; 2013 May; 62(5):735-40. PubMed ID: 22442162
[TBL] [Abstract][Full Text] [Related]
28. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
[TBL] [Abstract][Full Text] [Related]
29. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.
Segnan N; Senore C; Andreoni B; Azzoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; Ederle A; Fantin A; Ferrari A; Fracchia M; Ferrero F; Gasperoni S; Recchia S; Risio M; Rubeca T; Saracco G; Zappa M;
Gastroenterology; 2007 Jun; 132(7):2304-12. PubMed ID: 17570205
[TBL] [Abstract][Full Text] [Related]
30. "Rescue" of Nonparticipants in Colorectal Cancer Screening: A Randomized Controlled Trial of Three Noninvasive Test Options.
Young GP; Chen G; Wilson CJ; McGrane E; Hughes-Barton DL; Flight IHK; Symonds EL
Cancer Prev Res (Phila); 2021 Aug; 14(8):803-810. PubMed ID: 34127509
[TBL] [Abstract][Full Text] [Related]
31. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use.
Santare D; Kojalo I; Huttunen T; Rikacovs S; Rucevskis P; Boka V; Leja M
Eur J Gastroenterol Hepatol; 2015 May; 27(5):536-43. PubMed ID: 25806603
[TBL] [Abstract][Full Text] [Related]
32. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
33. Should Screening Colonoscopy Be Offered From Age 50?
Brenner H; Zwink N; Ludwig L; Hoffmeister M
Dtsch Arztebl Int; 2017 Feb; 114(6):94-100. PubMed ID: 28266302
[TBL] [Abstract][Full Text] [Related]
34. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test.
McNamara D; Leen R; Seng-Lee C; Shearer N; Crotty P; Neary P; Walsh P; Boran G; O'Morain C
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1415-21. PubMed ID: 25244415
[TBL] [Abstract][Full Text] [Related]
35. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
36. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
37. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
38. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
[TBL] [Abstract][Full Text] [Related]
39. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
